株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

米国の固形腫瘍検査市場:技術、癌タイプ、バイオマーカータイプ、用途、エンドユーザー、地域別、および競合情勢、分析と予測(2019年~2030年)

U.S. Solid Tumor Testing Market: Focus on Technology, Cancer Type, Biomarker Type, Application, End User, State Region, and Competitive Landscape - Analysis and Forecast, 2019-2030

発行 BIS Research Inc. 商品コード 940007
出版日 ページ情報 英文 279 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.31円で換算しております。
米国の固形腫瘍検査市場:技術、癌タイプ、バイオマーカータイプ、用途、エンドユーザー、地域別、および競合情勢、分析と予測(2019年~2030年) U.S. Solid Tumor Testing Market: Focus on Technology, Cancer Type, Biomarker Type, Application, End User, State Region, and Competitive Landscape - Analysis and Forecast, 2019-2030
出版日: 2020年06月02日 ページ情報: 英文 279 Pages
概要

米国の固形腫瘍検査市場は2030年にはに153億9,640万米ドルに達すると予測されています。

当レポートは米国の固形腫瘍検査市場について調査しており、市場規模や機会、成長および抑制要因、技術・用途・癌タイプ・バイオマーカータイプ・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

エグゼクティブサマリー

第1章 製品の定義

第2章 市場の調査範囲

第3章 調査手法

第4章 市場概要

  • 定義
  • 固形腫瘍検査技術
  • 市場規模と成長性
  • 業界参入企業の情勢

第5章 米国における固形腫瘍の疫学

第6章 業界考察

  • 遺伝子検査の規制
    • FDA規制
    • CMS規制
  • 償還シナリオ
    • 研究所産業への影響

第7章 市場力学

  • 市場成長要因
    • 癌発生率の上昇
    • シーケンスのコスト削減
    • 市場における無機成長戦略の採用増加
    • 国立癌研究所からの調査資金の増加
    • 遺伝子検査の採用増加の見通し
  • 抑制要因
    • 米国での償還カット
    • 米国での患者保護および手頃な価格のケア法実施の見通し
    • 高い価格圧力
  • 米国の市場機会
    • 大きな消費者基盤のための情報学と技術革新
    • D2C検査サービス市場の簇出

第8章 競合情勢

  • 主な戦略と開発
    • 相乗的活動
    • 承認
    • 製品の発売、強化、拡張
    • 買収と合併
  • 製品シナリオ
  • 資金調達シナリオ
  • 市場シェア分析
  • 成長シェア分析(機会マッピング)
    • 企業別
    • 技術別
    • 用途別
    • 癌タイプ別

第9章 米国市場:技術別

  • 概観
  • 次世代シーケンシング
  • In Situハイブリダイゼーション
  • ポリメラーゼ連鎖反応
  • 免疫組織化学
  • その他の技術

第10章 米国市場:癌タイプ別

  • 概観
  • 乳癌
  • 前立腺がん
  • 大腸がん
  • 肺癌
  • 黒色腫
  • 子宮内膜癌
  • 甲状腺癌
  • 脳がん
  • 卵巣がん
  • 肝臓がん
  • その他のがんの種類

第11章 米国市場:バイオマーカータイプ別

  • 概観
  • 遺伝的バイオマーカー
  • タンパク質バイオマーカー
  • その他のバイオマーカー

第12章 米国市場:用途別

  • 概観
  • 臨床
  • 調査

第13章 米国市場:エンドユーザー別

  • 概観
  • 病院・診断研究所・参考検査室
  • 製薬・バイオテクノロジー企業
  • 受託調査機関
  • 学術調査機関
  • その他

第14章 米国市場:地域別

  • 概観
  • 南部
  • 中西部
  • 大西洋岸中部
  • 西部
  • 南西部
  • ニューイングランド

第15章 企業プロファイル

  • 概観
  • Abbott Laboratories
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories, Inc.
  • ASURAGEN, INC.
  • Cancer Genetics Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • ARUP Laboratories
  • Invivoscribe, Inc.
  • NeoGenomics Laboratories, Inc.
  • Invitae Corporation
  • Opko Health
  • Laboratory Corporation of America Holdings
  • OmniSeq
  • Nanostring Technologies
  • Guardant Health
  • Personal Genome Diagnostics
  • Caris Life Sciences
  • Caris Life Sciences
  • Genomic Testing Cooperative
  • ArcherDX, Inc.
図表

List of Tables

  • Table 4.1: Solid Tumor Testing Technologies for Clinical Laboratories
  • Table 4.2: Technological Trends in Solid Tumor Testing Market
  • Table 4.3: Industry Participants Landscape in the U.S Solid Tumor Testing Market
  • Table 6.1: Examples of New CPT Codes Under the CMS
  • Table 6.2: New Payment Amounts for ADLTs
  • Table 7.1: Consolidated Variations in Medicaid & Medicare Revenues Reported by U.S. Majors as Per PAMA
  • Table 8.1: Market Players With Key Product Listing
  • Table 8.2: Cancer Moonshot Initiative Partners
  • Table 11.1: FDA-Approved Stratification Biomarkers for Targeted Therapy in Oncology

List of Figures

  • Figure 1: NCI Fiscal Budget Year on Year, 2013-2018
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on the U.S. Solid Tumor Testing Market
  • Figure 3: U.S. Solid Tumor Testing Market (by Technology), $Million, 2019 and 2030
  • Figure 4: U.S. Solid Tumor Testing Market (by Cancer Type), $Million, 2019 and 2030
  • Figure 5: U.S. Solid Tumor Testing Market (by Biomarker Type), $Million, 2019 and 2030
  • Figure 6: U.S. Solid Tumor Testing Market (by Application), $Million, 2019 and 2030
  • Figure 7: U.S. Solid Tumor Testing Market (by End User), $Million, 2019 and 2030
  • Figure 8: Top 5 Contributing States to the U.S. Solid Tumor Testing Market
  • Figure 2.1: U.S. Solid Tumor Testing Market Segmentation
  • Figure 3.1: U.S. Solid Tumor Testing Market Research Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
  • Figure 4.1: U.S. Solid Tumor Testing Market 2019-2030
  • Figure 5.1: Type of Solid Tumors
  • Figure 5.2: Estimated Percent of New Cancer Cases (by Sex), United States, 2020
  • Figure 5.3: Expected Cancers Cases in the U.S. (by State), 2020
  • Figure 5.4: Relative Number of Expected Cancers Cases (by State), 2020
  • Figure 5.5: Relative Percent of Expected Cancers Cases (by Region), 2020
  • Figure 5.6: Prevalence of Different Cancers Across the U.S. (2013-2017) *
  • Figure 7.1: Market Dynamics of U.S. Solid Tumor Testing Market
  • Figure 7.2: Cancer Cases Projections, 2015-2020
  • Figure 7.3: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
  • Figure 7.4: Synergistic Activities, 2017-2019
  • Figure 7.5: SBIR and STTR Grants and Contract Funding, 2008-2018
  • Figure 7.6: NCI Fiscal Budget Year on Year, 2013-2018
  • Figure 7.7: Reimbursement Cuts Adopted for Oncology Testing, as per PAMA Revisions
  • Figure 8.1: Share of Key Developments and Strategies, January 2017-December 2019
  • Figure 8.2: Synergistic Activities Share (by Company), January 2017-December 2019
  • Figure 8.3: Approvals Share (by Company), January 2017-December 2019
  • Figure 8.4: Product Launches and Expansion Share (by Company), January 2017-December 2019
  • Figure 8.5: Acquisitions and Mergers Share (by Company), January 2017-December 2019
  • Figure 8.6: NCI Budget Allocation, FY2015-FY2018
  • Figure 8.7: Fund Allocation for Cancer Moonshot Program
  • Figure 8.8: Market Share Analysis for the U.S. Solid Tumor Testing Market, 2019
  • Figure 8.9: Growth Share Matrix for U.S. Solid Tumor Testing Market (by Company), 2019
  • Figure 8.10: Growth Share Matrix for U.S. Solid Tumor Testing Market (by Technology), 2019
  • Figure 8.11: Growth Share Matrix for U.S. Solid Tumor Testing Market (by Application), 2019
  • Figure 8.12: Growth Share Matrix for U.S Solid Tumor Testing Market (by Cancer Type), 2019
  • Figure 9.1: U.S. Solid Tumor Testing Market (by Technology), 2019-2030
  • Figure 9.2: U.S. Solid Tumor Testing Market (for NGS), 2019-2030
  • Figure 9.3: U.S. Solid Tumor Testing Market (for Type of NGS Sequencing), 2019-2030
  • Figure 9.4: U.S. Solid Tumor Testing Market (for ISH), 2019-2030
  • Figure 9.5: U.S. Solid Tumor Testing Market (for PCR), 2019-2030
  • Figure 9.6: U.S. Solid Tumor Testing Market (for IHC), 2019-2030
  • Figure 9.7: U.S. Solid Tumor Testing Market (for Other Technologies), 2019-2030
  • Figure 10.1: Economic Burden of Major Cancer Types on the U.S. Economy, 2010-2018
  • Figure 10.2: U.S. Solid Tumor Testing Market (by Cancer Type), 2019-2030
  • Figure 10.3: Prevalence of Breast Cancer in U.S., 2013-2017
  • Figure 10.4: U.S. Solid Tumor Testing Market (for Breast Cancer), 2019-2030
  • Figure 10.5: Total Market Size for U.S. Solid Tumor Testing Market (for Breast Cancer, by Technology), 2019 and 2030
  • Figure 10.6: Prevalence of Prostate Cancer in U.S., 2013-2017
  • Figure 10.7: U.S. Solid Tumor Testing Market (for Prostate Cancer), 2019-2030
  • Figure 10.8: Total Market Size for U.S. Solid Tumor Testing Market (for Prostate Cancer, by Technology), 2019 and 2030
  • Figure 10.9: Prevalence of Colorectal Cancer in U.S., 2013-2017
  • Figure 10.10: U.S. Solid Tumor Testing Market (for Colorectal Cancer), 2019-2030
  • Figure 10.11: Total Market Size for U.S. Solid Tumor Testing Market (for Colorectal Cancer, by Technology), 2019 and 2030
  • Figure 10.12: Prevalence of Lung Cancer in U.S., 2013-2017
  • Figure 10.13: U.S. Solid Tumor Testing Market (for Lung Cancer), 2019-2030
  • Figure 10.14: Total Market Size for U.S. Solid Tumor Testing Market (for Lung Cancer, by Technology), 2019 and 2030
  • Figure 10.15: Prevalence of Melanoma in U.S., 2013-2017
  • Figure 10.16: U.S. Solid Tumor Testing Market (for Melanoma), 2019-2030
  • Figure 10.17: Total Market Size for U.S. Solid Tumor Testing Market (for Melanoma, by Technology), 2019 and 2030
  • Figure 10.18: Prevalence of Endometrial Cancer in U.S., 2013-2017
  • Figure 10.19: U.S. Solid Tumor Testing Market (for Endometrial Cancer), 2019-2030
  • Figure 10.20: Total Market Size for U.S. Solid Tumor Testing Market (for Endometrial Cancer, by Technology), 2019 and 2030
  • Figure 10.21: Prevalence of Thyroid Cancer in U.S., 2013-2017
  • Figure 10.22: U.S. Solid Tumor Testing Market (for Thyroid Cancer), 2019-2030
  • Figure 10.23: Total Market Size for U.S. Solid Tumor Testing Market (for Thyroid Cancer, by Technology), 2019 and 2030
  • Figure 10.24: Prevalence of Brain Cancer in U.S., 2013-2017
  • Figure 10.25: U.S. Solid Tumor Testing Market (for Brain Cancer), 2019-2030
  • Figure 10.26: Total Market Size for U.S. Solid Tumor Testing Market (for Brain Cancer, by Technology), 2019 and 2030
  • Figure 10.27: Prevalence of Ovarian Cancer in U.S., 2013-2017
  • Figure 10.28: U.S. Solid Tumor Testing Market (for Ovarian Cancer), 2019-2030
  • Figure 10.29: Total Market Size for U.S. Solid Tumor Testing Market (for Ovarian Cancer, by Technology), 2019 and 2030
  • Figure 10.30: Prevalence of Liver Cancer in U.S., 2013-2017
  • Figure 10.31: U.S. Solid Tumor Testing Market (for Liver Cancer), 2019-2030
  • Figure 10.32: Total Market Size for U.S. Solid Tumor Testing Market (for Liver Cancer, by Technology), 2019 and 2030
  • Figure 10.33: U.S. Solid Tumor Testing Market (for Other Cancer Types), 2019-2030
  • Figure 10.34: Total Market Size for U.S. Solid Tumor Testing Market (for Other Cancer Types, by Technology), 2019 and 2030
  • Figure 11.1: U.S. Solid Tumor Testing Market (by Type of Biomarker), 2019-2030
  • Figure 11.2: Technologies and Data Types for Genetic Biomarker Discovery
  • Figure 11.3: U.S. Solid Tumor Testing Market (for Genetic Biomarkers), 2019-2030
  • Figure 11.4: Technologies and Data Types for Protein Biomarker Discovery
  • Figure 11.5: U.S. Solid Tumor Testing Market (for Protein Biomarkers), 2019-2030
  • Figure 11.6: U.S. Solid Tumor Testing Market (for Other Biomarkers), 2019-2030
  • Figure 12.1: U.S. Solid Tumor Testing Market (by Application), 2019-2030
  • Figure 12.2: U.S. Solid Tumor Testing Market (for Clinical Applications), 2019-2030
  • Figure 12.3: U.S. Solid Tumor Testing Market (for Types of Clinical Applications), 2019-2030
  • Figure 12.4: U.S. Solid Tumor Testing Market (for Research Applications), 2019-2030
  • Figure 12.5: U.S. Solid Tumor Testing Market (for Types of Research Applications), 2019-2030
  • Figure 13.1: U.S. Solid Tumor Testing Market (by End User), 2019-2030
  • Figure 13.2: U.S. Solid Tumor Testing Market (for Hospitals, Diagnostic Laboratories, and Reference Laboratories), 2019-2030
  • Figure 13.3: U.S. Solid Tumor Testing Market (for Pharmaceutical and Biotechnology Companies), 2019-2030
  • Figure 13.4: U.S. Solid Tumor Testing Market (for Contract Research Organization), 2019-2030
  • Figure 13.5: U.S. Solid Tumor Testing Market (for Academic Research Institutions), 2019-2030
  • Figure 13.6: U.S. Solid Tumor Testing Market (for Other End Users), 2019-2030
  • Figure 14.1: U.S. Solid Tumor Testing Market (by State Region), 2019-2030
  • Figure 14.2: Growth in Top 5 States in the U.S. Solid Tumor Testing Market, 2019-2030
  • Figure 14.3: The South U.S. Solid Tumor Testing Market, 2019-2030
  • Figure 14.4: The South U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
  • Figure 14.5: The Midwest U.S. Solid Tumor Testing Market, 2019-2030
  • Figure 14.6: The Midwest U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
  • Figure 14.7: The Mid-Atlantic U.S. Solid Tumor Testing Market, 2019-2030
  • Figure 14.8: The Mid-Atlantic U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
  • Figure 14.9: The West U.S. Solid Tumor Testing Market, 2019-2030
  • Figure 14.10: The West U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
  • Figure 14.11: The Southwest U.S. Solid Tumor Testing Market, 2019-2030
  • Figure 14.12: The Southwest U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
  • Figure 14.13: New England Solid Tumor Testing Market, 2019-2030
  • Figure 15.1: Total Number of Companies Profiled
  • Figure 15.2: Abbott Laboratories: Portfolio
  • Figure 15.3: Abbott Laboratories: Overall Financials, 2017-2019
  • Figure 15.4: Abbott Laboratories: Revenue (by Segment), 2017-2019
  • Figure 15.5: Abbott Laboratories: Revenue Split for Diagnostics, 2017-2019
  • Figure 15.6: Abbott Laboratories: Revenue (by Region), 2017-2019
  • Figure 15.7: Abbott Laboratories: R&D Expenditure, 2017-2019
  • Figure 15.8: Abbott Laboratories: SWOT Analysis
  • Figure 15.9: Illumina, Inc.: Portfolio
  • Figure 15.10: Illumina, Inc.: Overall Financials, 2017-2019
  • Figure 15.11: Illumina, Inc.: Revenue (by Segment), 2017-2019
  • Figure 15.12: Illumina, Inc.: Revenue (by Region), 2017-2019
  • Figure 15.13: Illumina, Inc.: R&D Expenditure, 2017-2019
  • Figure 15.14: Illumina, Inc.: SWOT Analysis
  • Figure 15.15: F. Hoffmann-La Roche Ltd: Portfolio
  • Figure 15.16: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
  • Figure 15.17: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2017-2019
  • Figure 15.18: F. Hoffmann-La Roche Ltd: Sales (by Region), 2017-2019
  • Figure 15.19: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
  • Figure 15.20: F. Hoffmann-La Roche: SWOT Analysis
  • Figure 15.21: Bio-Rad Laboratories, Inc.: Portfolio
  • Figure 15.22: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
  • Figure 15.23: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
  • Figure 15.24: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
  • Figure 15.25: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
  • Figure 15.26: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 15.27: ASURAGEN, INC.: Portfolio
  • Figure 15.28: ASURAGEN, INC.: SWOT Analysis
  • Figure 15.29: Cancer Genetics Inc.: Portfolio
  • Figure 15.30: Cancer Genetics Inc.: Overall Financials, 2016-2018
  • Figure 15.31: Cancer Genetics Inc.: Sales (by Segment), 2016-2018
  • Figure 15.32: Cancer Genetics Inc.: Sales (by Region), 2016-2018
  • Figure 15.33: Cancer Genetics Inc.: R&D Expenditure, 2016-2018
  • Figure 15.34: Cancer Genetics Inc.: SWOT Analysis
  • Figure 15.35: QIAGEN N.V.: Portfolio
  • Figure 15.36: QIAGEN N.V.: Overall Financials, 2017-2019
  • Figure 15.37: QIAGEN N.V.: Revenue (by Segment), 2017-2019
  • Figure 15.38: QIAGEN N.V.: Revenue (by Region), 2017-2019
  • Figure 15.39: QIAGEN N.V.: R&D Expenditure, 2017-2019
  • Figure 15.40: QIAGEN N.V.: SWOT Analysis
  • Figure 15.41: Quest Diagnostics Incorporated: Portfolio
  • Figure 15.42: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
  • Figure 15.43: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2017-2019
  • Figure 15.44: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 15.45: ARUP Laboratories: Portfolio
  • Figure 15.46: ARUP Laboratories: SWOT Analysis
  • Figure 15.47: Invivoscribe, Inc.: Portfolio
  • Figure 15.48: Invivoscribe, Inc.: SWOT Analysis
  • Figure 15.49: NeoGenomics Laboratories, Inc.: Portfolio
  • Figure 15.50: NeoGenomics Laboratories, Inc.: Overall Financials, 2017-2019
  • Figure 15.51: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2017-2019
  • Figure 15.52: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2017-2019
  • Figure 15.53: NeoGenomics Laboratories, Inc.: SWOT Analysis
  • Figure 15.54: Invitae Corporation: Portfolio
  • Figure 15.55: Invitae Corporation: Overall Financials, 2017-2019
  • Figure 15.56: Invitae Corporation: Revenue (by Segment), 2017-2019
  • Figure 15.57: Invitae Corporation: Revenue (by Geography), 2017-2019
  • Figure 15.58: Invitae Corporation: R&D Expenditure, 2017-2019
  • Figure 15.59: Invitae Corporation: SWOT Analysis
  • Figure 15.60: Opko Health: Portfolio
  • Figure 15.61: Opko Health: Overall Financials, 2017-2019
  • Figure 15.62: Opko Health: Revenue (by Segment), 2017-2019
  • Figure 15.63: Opko Health: Revenue (by Region), 2017-2019
  • Figure 15.64: Opko Health: R&D Expenditure, 2017-2019
  • Figure 15.65: Opko Health: SWOT Analysis
  • Figure 15.66: Laboratory Corporation of America Holdings: Portfolio
  • Figure 15.67: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
  • Figure 15.68: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
  • Figure 15.69: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
  • Figure 15.70: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 15.71: OmniSeq: Portfolio
  • Figure 15.72: OmniSeq: SWOT Analysis
  • Figure 15.73: Nanostring Technologies: Portfolio
  • Figure 15.74: Nanostring Technologies: Overall Financials, 2017-2019
  • Figure 15.75: Nanostring Technologies: Revenue (by Segment), 2017-2019
  • Figure 15.76: Nanostring Technologies: Revenue (by Region), 2017-2019
  • Figure 15.77: Nanostring Technologies: SWOT Analysis
  • Figure 15.78: Guardant Health: Portfolio
  • Figure 15.79: Guardant Health: Overall Financials, 2017-2019
  • Figure 15.80: Guardant Health: Revenue (by Segment), 2017-2019
  • Figure 15.81: Guardant Health: Revenue (by Region), 2017-2019
  • Figure 15.82: Guardant Health: SWOT Analysis
  • Figure 15.83: Personal Genome Diagnostics: Portfolio
  • Figure 15.84: Personal Genome Diagnostics: SWOT Analysis
  • Figure 15.85: HTG Molecular Diagnostics: Portfolio
  • Figure 15.86: HTG Molecular Diagnostics: Overall Financials, 2017-2019
  • Figure 15.87: HTG Molecular Diagnostics: Revenue (by Segment), 2017-2019
  • Figure 15.88: HTG Molecular Diagnostics: SWOT Analysis
  • Figure 15.89: Caris Life Sciences: Portfolio
  • Figure 15.90: Caris Life Sciences: SWOT Analysis
  • Figure 15.91: Genomic Testing Cooperative: Portfolio
  • Figure 15.92: Genomic Testing Cooperative: SWOT Analysis
  • Figure 15.93: ArcherDX, Inc.: Portfolio
  • Figure 15.94: ArcherDX, Inc.: SWOT Analysis
目次
Product Code: BH197A

"U.S. Solid Tumor Testing Market to Reach $15,396.4 Million by 2030."

Market Report Coverage - U.S. Solid Tumor Testing

Market Segmentation

  • By Product: Kits and Services
  • By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Immunohistochemistry (IHC) and Other Technologies
  • By Application: Clinical and Research Segments
  • By End User: Hospital, Diagnostic Laboratories and Reference Laboratories, Pharmaceutical and Biotechnology Company, Contract Research Organizations, Academic Research Institutions and Other End Users
  • By Cancer Type: Breast Cancer, Colorectal Cancer, Melanoma, Thyroid Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Endometrial Cancer, Brain Cancer, Liver Cancer and Other Cancers

Regional Segmentation

  • U.S. - State Specific Stratification

Growth Drivers

  • Rising Incidence of Cancers
  • Increasing Adoption of Inorganic Growth Strategies in the Market
  • Increasing Research Funding from National Cancer Institute

Market Challenges

  • Reimbursement Cuts in the U.S.
  • High Pricing Pressure
  • Expected Implementation of Patient Protection and Affordable Care Act (PPACA) in the U.S.

Market Opportunities

  • Informatics and Technological Innovation for Larger Consumer Base
  • Expected Increase in the Adoption of Genetic Testing

Key Companies Profiled

Abbott Laboratories, Laboratory Corporation of America, Quest Diagnostics Incorporated, Illumina, F. Hoffmann-La Roche, ARUP Laboratories, Bio-Rad Laboratories Inc., Asuragen Inc., Cancer Genetics Inc., Invitae Corporation, NeoGenomics Laboratories, Inc., and QIAGEN N.V

Key Questions Answered:

  • What is solid tumor testing? How have different testing technologies for solid tumor testing evolved over the centuries?
  • What are the major market drivers, challenges, and opportunities in the U.S. solid tumor testing market?
  • What was the U.S. solid tumor testing market size in terms of revenue in 2019? How is the market expected to evolve in the upcoming years? What is the expected market size in 2030?
  • How is each segment of the U.S. solid tumor testing market expected to grow during the forecast period between 2020 to 2030, and what is the revenue expected to be generated by each of the segments by the end of 2030?
  • What are the developmental strategies implemented by the key players to sustain in the competitive market?
  • What is the growth potential of the solid tumor testing market in several states across the U.S.?
  • Which product among the two (kits and services) are offered by key players such as Laboratory Corporation of America, Quest Diagnostics Incorporated, Abbott Laboratories, Illumina Inc., Qiagen N.V., and F. Hoffmann-La Roche Ltd.?
  • Which technology was leading the market in 2019 and expected to dominate the market by 2030 and why?
  • Which application type was leading the market in 2019 and is expected to dominate the market in 2030 and why?
  • Which region dominated the U.S. solid tumor testing market in 2019, and what are the expected trends from each of the regions in the forecast period 2020-2030?

Market Overview

The term solid tumor refers to abnormal cellular growths, which generally comprise sarcomas, carcinomas, and lymphomas. The current solid tumor testing market is mainly dominated by several diagnostic majors, such as Quest Diagnostics Incorporated, Laboratory Corporation of America, Foundation Medicine, which offer a wide variety of testing services for solid tumors. These testing services ranges from molecular-genetic tests to liquid biopsies for the confirmatory diagnosis of solid tumors. The key players in the product segment include Illumina, Abbott Laboratories and ThermoFisher Scientific, which offer kits for the analysis of solid tumors.

The solid tumor tests are generally based on technologies such as fluorescence in situ hybridization (FISH), immunohistochemistry (INC), bi-directional sanger sequencing, polymerase chain reaction (PCR), next-generation sequencing (NGS), and other technologies. The underlying utility of diagnostic testing for solid tumors is based on the identification of clinically actionable gene mutations, which provide crucial information on diagnosis, prognosis, and theranosis of solid tumors and thereby facilitate clinical work-up, treatment management, and therapeutic selection.

The existing market of solid tumor testing is favored by multiple factors, which include rising government initiatives, increasing incidence of cancer, thereby increasing the utilization of testing technologies to identify the underlying mutations. In addition, an increasing number of product approvals and launches pertaining to U.S. solid tumor testing market will provide a lucrative growth for this market. Moreover, increasing use of biomarkers in cancer profiling is also one of the key driving factors for solid tumor testing market.

Government funding is also one of the major growth factors for the solid tumor testing market, because increasing funding by the government is expected to facilitate research institutes and key players to develop as well as market novel assays useful for the diagnosis of several tumors. Increasing funding will lead to liquidity of the solid tumor market, and thus, companies will develop various testing options for solid tumors to identify the underlying mutations that serve as a possible cause for the disease. All these factors are therefore expected to contribute to the market growth during the forecast period.

Within the research report, the market is segmented on the basis of product type, technology, application, end user, cancer type, biomarker type and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises state-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360-degree coverage of the domain.

Competitive Landscape

Major players, including Laboratory Corporation of America, QIAGEN N.V., Illumina, Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Quest Diagnostic Incorporated, and Thermo Fisher Scientific, among others, led the number of synergistic developments (partnerships and alliances) witnessed by the market. On the basis of state, California is expected to retain a leading position throughout the forecast period 2020-2030, followed by Florida. This is a result of the presence of leading industry players in this region, coupled up with the highest prevalence of solid tumors in 2017.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Market Scope

  • 2.1 Scope of Work
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 U.S. Solid Tumors Testing Market: Research Methodology
  • 3.2 Data Sources
  • 3.3 Secondary Data Sources
  • 3.4 Market Estimation Model
  • 3.5 Criteria for Company Profiling

4 Market Overview

  • 4.1 Definition
  • 4.2 Solid Tumor Testing Technologies
  • 4.3 Market Size and Growth Potential, $Million, 2019-2030
  • 4.4 Industry Participants Landscape

5 Epidemiology of Solid Tumors in U.S.

6 Industry Insights

  • 6.1 Regulation of Genetic Tests
    • 6.1.1 FDA Regulation
    • 6.1.2 CMS Regulation
  • 6.2 Reimbursement Scenario
    • 6.2.1 Impact on Laboratory Industry

7 Market Dynamics

  • 7.1 Market Drivers
    • 7.1.1 Rising Incidence of Cancers
    • 7.1.2 Decreasing Cost of Sequencing
    • 7.1.3 Increasing Adoption of Inorganic Growth Strategies in the Market
    • 7.1.4 Increasing Research Funding from National Cancer Institute
    • 7.1.5 Expected Increase in Adoption of Genetic Testing
  • 7.2 Restraints
    • 7.2.1 Reimbursement Cuts in the U.S.
    • 7.2.2 Expected Implementation of Patient Protection and Affordable Care Act in the U.S.
    • 7.2.3 High Pricing Pressure
  • 7.3 U.S. Market Opportunities
    • 7.3.1 Informatics and Technological Innovation for Larger Consumer Base
    • 7.3.2 Mushrooming Direct-to-Consumer (DTC) Testing Services Market

8 Competitive Landscape

  • 8.1 Key Strategies and Developments
    • 8.1.1 Synergistic Activities
    • 8.1.2 Approvals
    • 8.1.3 Product Launches, Enhancements and Expansion
    • 8.1.4 Acquisitions and Mergers
  • 8.2 Product Scenario
  • 8.3 Funding Scenario
  • 8.4 Market Share Analysis
  • 8.5 Growth Share Analysis (Opportunity Mapping)
    • 8.5.1 By Company
    • 8.5.2 By Technology
    • 8.5.3 By Application
    • 8.5.4 By Cancer Type

9 U.S. Solid Tumor Testing Market (by Technology)

  • 9.1 Overview
  • 9.2 Next-Generation Sequencing
  • 9.3 In Situ Hybridization
  • 9.4 Polymerase Chain Reaction
  • 9.5 Immunohistochemistry
  • 9.6 Other Technologies

10 U.S. Solid Tumor Testing Market (by Cancer Type)

  • 10.1 Overview
  • 10.2 Breast Cancer
  • 10.3 Prostate Cancer
  • 10.4 Colorectal Cancer
  • 10.5 Lung Cancer
  • 10.6 Melanoma
  • 10.7 Endometrial Cancer
  • 10.8 Thyroid Cancer
  • 10.9 Brain Cancer
  • 10.10 Ovarian Cancer
  • 10.11 Liver Cancer
  • 10.12 Other Cancer Types

11 U.S. Solid Tumor Testing Market (by Type of Biomarker)

  • 11.1 Overview
  • 11.2 Genetic Biomarkers
  • 11.3 Protein Biomarkers
  • 11.4 Other Biomarkers

12 U.S. Solid Tumor Testing Market (by Application)

  • 12.1 Overview
  • 12.2 Clinical
  • 12.3 Research

13 U.S. Solid Tumor Testing Market (by End User)

  • 13.1 Overview
  • 13.2 Hospitals, Diagnostic Laboratories, and Reference Laboratories
  • 13.3 Pharmaceutical and Biotechnology Companies
  • 13.4 Contract Research Organizations
  • 13.5 Academic Research Institutions
  • 13.6 Other End Users

14 U.S. Solid Tumor Testing Market (by State Region)

  • 14.1 Overview
  • 14.2 The South U.S.
  • 14.3 The Midwest U.S.
  • 14.4 The Mid-Atlantic U.S.
  • 14.5 The West U.S.
  • 14.6 The Southwest U.S.
  • 14.7 New England

15 Company Profiles

  • 15.1 Overview
  • 15.2 Abbott Laboratories
    • 15.2.1 Company Overview
    • 15.2.2 Role of Abbott Laboratories in the U.S. Solid Tumor Testing Market
    • 15.2.3 Financials
    • 15.2.4 Key Insights About Financial Health of the Company
    • 15.2.5 SWOT Analysis
  • 15.3 Illumina, Inc.
    • 15.3.1 Company Overview
    • 15.3.2 Role of Illumina, Inc. in the U.S. Solid Tumor Testing Market
    • 15.3.3 Financials
    • 15.3.4 Key Insights About Financial Health of the Company
    • 15.3.5 SWOT Analysis
  • 15.4 F. Hoffmann-La Roche Ltd.
    • 15.4.1 Company Overview
    • 15.4.2 Role of F. Hoffmann-La Roche Ltd in the U.S. Solid Tumor Testing Market
    • 15.4.3 Financials
    • 15.4.4 Key Insights About Financial Health of the Company
    • 15.4.5 SWOT Analysis
  • 15.5 Bio-Rad Laboratories, Inc.
    • 15.5.1 Company Overview
    • 15.5.2 Role of Bio-Rad Laboratories, Inc. in the U.S. Solid Tumor Testing Market
    • 15.5.3 Financials
    • 15.5.4 Key Insights About Financial Health of the Company
    • 15.5.5 SWOT Analysis
  • 15.6 ASURAGEN, INC.
    • 15.6.1 Company Overview
    • 15.6.2 Role of ASURAGEN, INC. in the U.S. Solid Tumor Testing Market
    • 15.6.3 SWOT Analysis
  • 15.7 Cancer Genetics Inc.
    • 15.7.1 Company Overview
    • 15.7.2 Role of Cancer Genetics Inc.in the U.S. Solid Tumor Testing Market
    • 15.7.3 Financials
    • 15.7.4 Key Insights About Financial Health of the Company
    • 15.7.5 SWOT Analysis
  • 15.8 QIAGEN N.V.*
    • 15.8.1 Company Overview
    • 15.8.2 Role of QIAGEN N.V. in the U.S. Solid Tumor Testing Market
    • 15.8.3 Financials
    • 15.8.4 Key Insights about Financial Health of the Company
    • 15.8.5 SWOT Analysis
  • 15.9 Quest Diagnostics Incorporated
    • 15.9.1 Company Overview
    • 15.9.2 Role of Quest Diagnostics Limited in the U.S. Solid Tumor Testing Market
    • 15.9.3 Financials
    • 15.9.4 SWOT Analysis
  • 15.10 ARUP Laboratories
    • 15.10.1 Company Overview
    • 15.10.2 Role of ARUP Laboratories in the U.S. Solid Tumor Testing Market
    • 15.10.3 SWOT Analysis
  • 15.11 Invivoscribe, Inc.
    • 15.11.1 Company Overview
    • 15.11.2 Role of Invivoscribe, Inc. in the U.S. Solid Tumor Testing Market
    • 15.11.3 SWOT Analysis
  • 15.12 NeoGenomics Laboratories, Inc.
    • 15.12.1 Company Overview
    • 15.12.2 Role of NeoGenomics Laboratories, Inc. in the U.S. Solid Tumor Testing Market
    • 15.12.3 Financials
    • 15.12.4 Key Insights About Financial Health of the Company
    • 15.12.5 SWOT Analysis
  • 15.13 Invitae Corporation
    • 15.13.1 Company Overview
    • 15.13.2 Role of Invitae Corporation, Inc. in the U.S. Solid Tumor testing Market
    • 15.13.3 Financials
    • 15.13.4 Key Insights About Financial Health of the Company
    • 15.13.5 SWOT Analysis
  • 15.14 Opko Health
    • 15.14.1 Company Overview
    • 15.14.2 Role of Opko Health, Inc. in the U.S. Solid Tumor Testing Market
    • 15.14.3 Financials
    • 15.14.4 Key Insights About Financial Health of the Company
    • 15.14.5 SWOT Analysis
  • 15.15 Laboratory Corporation of America Holdings
    • 15.15.1 Company Overview
    • 15.15.2 Role of Laboratory Corporation of America Holdings in the U.S. Solid Tumor Testing Market
    • 15.15.3 Financials
    • 15.15.4 SWOT Analysis
  • 15.16 OmniSeq
    • 15.16.1 Company Overview
    • 15.16.2 Role of OmniSeq in the U.S. Solid Tumor Testing Market
    • 15.16.3 SWOT Analysis
  • 15.17 Nanostring Technologies
    • 15.17.1 Company Overview
    • 15.17.2 Role of Nanostring Technologies in the U.S. Solid Tumor Testing Market
    • 15.17.3 Financials
    • 15.17.4 SWOT Analysis
  • 15.18 Guardant Health
    • 15.18.1 Company Overview
    • 15.18.2 Role of Guardant Health in the U.S. Solid Tumor Testing Market
    • 15.18.3 Financials
    • 15.18.4 SWOT Analysis
  • 15.19 Personal Genome Diagnostics
    • 15.19.1 Company Overview
    • 15.19.2 Role of Personal Genome Diagnostics in the U.S. Solid Tumor Testing Market
    • 15.19.3 SWOT Analysis
  • 15.20 HTG Molecular Diagnostics
    • 15.20.1 Company Overview
    • 15.20.2 Role of HTG Molecular Diagnostics in the U.S. Solid Tumor Testing Market
    • 15.20.3 Financials
    • 15.20.4 SWOT Analysis
  • 15.21 Caris Life Sciences
    • 15.21.1 Company Overview
    • 15.21.2 Role Caris Life Sciences in the U.S Solid Tumor Testing Market
    • 15.21.3 SWOT Analysis
  • 15.22 Genomic Testing Cooperative
    • 15.22.1 Company Overview
    • 15.22.2 Role of Genome Testing Cooperative in the U.S Solid Tumor Testing Market
    • 15.22.3 SWOT Analysis
  • 15.23 ArcherDX, Inc.
    • 15.23.1 Company Overview
    • 15.23.2 Role of ArcherDX, Inc. in the U.S Solid Tumor Testing Market
    • 15.23.3 SWOT Analysis